2025 年 5 月 14 日 2025 年第三次临时股东大会会议资料 2025 年第三次临时股东大会会议资料 天士力医药集团股份有限公司 2025 年第三次临时股东大会会议资料 天士力医药集团股份有限公司 2025 年第三次临时股东大会议程 一、会议时间： 现场会议召开时间：2025 年 5 月 14 日 15 点 30 分 网络投票系统及投票时间： 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2025 年 5 月 14 日 至 2025 年 5 月 14 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东大会 召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平台的 投票时间为股东大会召开当日的 9:15-15:00。 （四）宣读议案并请股东针对议案发表意见 | 序号 | | | 议案名称 | | --- | --- | --- | --- | | 非累积投票议案 | | | | | 1 | 关于增加经营范围并修订《公司章程》的议案 | | | | 2 | 关于公司 | 2025 | 年度担保预计的议 ...

Meeting Overview - The shareholders' meeting was held on May 7, 2025, at the Tianjin Beichen Technology Park [1] - The meeting was conducted with both on-site and online voting, presided over by the chairwoman, Zhou Hui [1] Attendance - Out of 15 current directors, 12 attended the meeting, while three were absent due to work commitments [2] - All 5 current supervisors attended the meeting, along with the board secretary and the financial director [2] Proposal Review - A proposal to increase the expected daily related transactions for 2025 was approved [3] - The voting for the proposal was a non-cumulative voting process, requiring a simple majority from the attending shareholders [3][4] Legal Witnessing - The meeting was legally witnessed by Inner Mongolia Jianzhong Law Firm, with lawyers Liu Hong and Zhang Xinyu present [5] - The legal opinion confirmed that the meeting's procedures and voting results were in compliance with relevant laws and regulations [5]

2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 证券代码：600535 证券简称：天士力 编号：临2025-041号 天士力医药集团股份有限公司 (一) 股东大会召开的时间：2025 年 5 月 7 日 | 1、出席会议的股东和代理人人数 | 1,049 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 300,832,102 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 30.0548 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议采取现场投票与网络投票相结合的方式召开及表决。会议由公司董事 会召集，根据《公司章程》有关规定，由董事长周辉女士现场主持本次会议。会议 的召集、召开符合有关法律、法规、规章和《公司章程》的规定。 (五) 公司董事、监事和董事会秘书的出席情况 1、公司在任董事15人，出席12人， ...

内蒙古建中律师事务所 关于天士力医药集团股份有限公司 2025 年第二次临时股东大会的法律意见书 2025 内建中券意字第 11 号 致：天士力医药集团股份有限公司 内蒙古建中律师事务所（以下称"本所"）受天士力医药集团股份有限公司 （以下称"贵公司"或"公司"）的委托，指派本所执业律师刘弘、张辛羽（以 下称"本所经办律师"）出席了贵公司 2025 年第二次临时股东大会（以下称"本 次股东大会"），并根据《中华人民共和国证券法》（以下称"《证券法》"）、 《中华人民共和国公司法》（以下称"《公司法》"）和中国证监会《上市公司 股东大会规则》（以下称"《股东大会规则》"）等法律、法规和规范性文件以 及《天士力医药集团股份有限公司章程》（以下称"《章程》"）的规定，就本 次股东大会的召集、召开程序、出席会议人员资格以及表决程序和表决结果的合 法有效性出具本法律意见书。 为出具本法律意见书，本所经办律师已对本次股东大会所涉及的有关事项及 文件资料进行了必要的核查和验证，且贵公司已对前述资料的真实性和准确性向 本所作了保证。 本法律意见书仅供贵公司为本次股东大会的适当目的使用，不得被任何人用 于其他任何目的。 本所同 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported Q1 2025 revenue of 2.055 billion yuan, a year-on-year increase of 0.30%, and a net profit attributable to shareholders of 314 million yuan, up 6.47% year-on-year. The pharmaceutical industrial revenue showed slight growth, and with the expected normalization of product shipments and the dual empowerment from China Resources Sanjiu, the growth rate is anticipated to improve quarterly in 2025 [5][6] - The company has a robust R&D pipeline with 98 products under development, including 33 innovative drugs. The completion of the transfer of control to China Resources Sanjiu is expected to enhance the company's competitive edge and development prospects [5][6] - The forecast for net profit attributable to shareholders for 2025-2027 is 1.165 billion, 1.411 billion, and 1.677 billion yuan, respectively, with corresponding EPS of 0.78, 0.94, and 1.12 yuan, indicating strong growth potential [2][5] Financial Summary - For 2025, the company expects revenue of 9.043 billion yuan, a 6.41% increase from 2024, and a net profit of 1.165 billion yuan, a 21.87% increase from 2024. The P/E ratio is projected to decrease from 23.20 in 2024 to 19.04 in 2025 [2][5] - The gross margin for Q1 2025 was 66.62%, with a net profit margin of 11.50%, reflecting a slight decrease compared to the previous year [5][6] - The company’s cash flow from operating activities is projected to be 1.251 billion yuan in 2025, indicating a healthy cash flow position [6]

Core Insights - The 2025 Wuzhen Health Conference recognized Tianshili (600535.SH) as a VIP strategic partner and awarded its products for innovation and popularity in the retail market [1] - The Chinese pharmaceutical retail market is projected to reach 501.9 billion yuan in 2024, driven by policy changes and demographic shifts [3] - Tianshili focuses on integrating traditional Chinese medicine with modern medical practices, targeting major disease areas such as cardiovascular, digestive, oncology, and central nervous system disorders [3][8] Company Strategy - Tianshili is transitioning from high-quality products to strong brand recognition, emphasizing a digital marketing system centered on health value [4] - The company employs various promotional strategies, including social media campaigns and educational initiatives, to enhance brand visibility and consumer engagement [5] - Tianshili collaborates with offline strategic partners to create specialized health centers, improving customer service and market penetration [7] Product Performance - In 2024, Tianshili's traditional Chinese medicine segment generated 6.024 billion yuan, with key products like Compound Danshen Dripping Pills and Yangxue Qingnao Granules showing significant sales growth [7] - The company has a robust pipeline for cardiovascular drugs, with ongoing clinical trials for 17 modern Chinese medicine products [10] - Tianshili's innovative products, such as Shao Ma Zhi Jiao Granules and Kun Xin Ning Granules, have received recognition in clinical guidelines, enhancing its market position [10] Innovation and Responsibility - Tianshili emphasizes the integration of modern technology with traditional Chinese medicine to enhance product efficacy and market competitiveness [8] - The company aims to create a three-dimensional innovation system that combines clinical value, digital technology, and patient services [10] - Tianshili's commitment to innovation is reflected in its continuous development of new products and improvement of existing ones, ensuring long-term sustainability [10]

Summary of Tianjin Tasly Pharmaceutical Conference Call Company Overview - **Company**: Tianjin Tasly Pharmaceutical - **Date**: Q1 2025 Conference Call Key Points Industry and Company Positioning - Tianjin Tasly is integrating into China Resources and is formulating a 15-year strategic plan to define its positioning and business development goals within the "One Body, Two Wings" model of China Resources Sanjiu [2][3] - The company is actively collaborating with various business units within the China Resources group to implement synergistic projects aimed at consolidating core businesses and exploring new growth opportunities [2][3] Financial Performance - In Q1 2025, the company achieved revenue of 2.055 billion yuan, with pharmaceutical industrial revenue at 1.842 billion yuan, a year-on-year increase of 1.83% [2][6] - Net profit attributable to shareholders was 314 million yuan, up 6.47% year-on-year, while the asset-liability ratio remained low at 19% [2][6] - Despite facing a 15% price drop in Compound Danshen Dripping Pills, sales volume and revenue remained stable, with expectations for a growth trend in the latter half of the year [2][11] Product Performance and Market Strategy - The Chinese medicine segment is expected to maintain stable growth, driven by the promotion of three core essential drug varieties in grassroots markets and rapid growth of potential products like Scan Paper Granules and Niuhuang Qingxin Pills [2][9] - The chemical drug segment focuses on a combination of imitation and innovation, with two main products, Shuilinjia and Diqing, expected to continue stable growth [2][10] - The biological drug segment, particularly the product Puyouke, is anticipated to maintain stability, with new growth opportunities following the approval of indications for cerebral infarction [2][10][18] Strategic Initiatives - The company is implementing the 6S management system to enhance operational efficiency and overall management quality [5][26] - A focus on academic promotion and market penetration for new indications, such as diabetic retinopathy, is expected to significantly expand market potential [11][12] - The synergy with China Resources Sanjiu's commercial system is expected to enhance market coverage and brand recognition for core products [13] Risk Management - The company acknowledges the risks associated with price reductions but believes they are manageable, as evidenced by stable sales and revenue despite price drops [14] - The expansion of the grassroots sales network and the introduction of new academic promotion initiatives are expected to mitigate risks and enhance market access [14] Future Outlook - The company aims to become a leader in innovative Chinese medicine and a prominent player in the healthcare market, with a focus on leveraging the advantages of the China Resources group [5][26] - Continuous efforts will be made to optimize product lines and enhance research and development management efficiency [26] Additional Insights - The company plans to adjust its compensation structure and consider cash incentive plans in the short term, with potential long-term equity incentive plans pending approval [22] - The integration with China Resources is expected to resolve competition issues within five years, with ongoing updates to be provided [23] This summary encapsulates the key insights from the conference call, highlighting Tianjin Tasly's strategic direction, financial performance, product outlook, and risk management strategies.

证券代码：600535 证券简称：天士力 编号：临2025-039号 天士力医药集团股份有限公司 一、召开会议的基本情况 (一) 股东大会类型和届次 2025年第三次临时股东大会 召开的日期时间：2025 年 5 月 14 日 15 点 30 分 召开地点：天津市北辰科技园区天士力现代中药城天士力医药集团股份有限公司 会议室 (五) 网络投票的系统、起止日期和投票时间 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 14 日 至2025 年 5 月 14 日 关于召开2025年第三次临时股东大会的通知 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东大 会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票 平台的投票时间为股东大会召开当日的 9:15-15:00。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1 股东大会召开日期：2025年5月14日 本次股东大会采用的网络投票系统：上海证 ...

证券代码：600535 证券简称：天士力 编号：临 2025-036 号 天士力医药集团股份有限公司 第九届董事会第 9 次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"或"本公司"）第九届董事 会第 9 次会议通知于 2025 年 4 月 22 日以书面方式发出，会议于 2025 年 4 月 27 日上午 10:00 在公司天津本部会议室以现场与视频相结合的方式召开，会议应到 董事 15 人，实到 14 人，董事王亮先生因工作原因未能出席书面委托董事王克先 生代为行使表决权，公司监事、部分高管列席会议。会议符合《公司法》和《公 司章程》的有关规定，会议合法、有效。会议由公司董事长周辉女士主持，经与 会人员逐项审议，通过了以下议案： 1、2025 年第一季度报告 内容详见公司在上海证券交易所网站（www.sse.com.cn）发布的《2025 年第 一季度报告》。本议案已经董事会审计委员会 2025 年第四次工作会议事前认可并 审议通过。 表决情况为：有效表决票 ...

TASLY PHARMACEUTICAL GROUP CO., LTD. 天士力医药集团股份有限公司 章 程 二零二五年四月 | 第二章 | 经营宗旨和范围 3 | | | --- | --- | --- | | 第三章 | 股份 3 | | | 第一节 | 股份发行 | 3 | | 第二节 | 股份增减和回购 4 | | | 第三节 | 股份转让 | 5 | | 第四章 | 股东和股东大会 6 | | | 第一节 | 股东 6 | | | 第二节 | 股东大会的一般规定 8 | | | 第三节 | 股东大会的召集 10 | | | 第四节 | 股东大会的提案与通知 11 | | | 第五节 | 股东大会的召开 12 | | | 第六节 | 股东大会的表决和决议 15 | | | 第五章 | 党委 20 | | | 第六章 | 董事会 | 21 | | 第一节 | 董事 21 | | | 第二节 | 独立董事 | 23 | | 第三节 | 董事会 | 27 | | 第四节 | 董事会秘书 | 31 | | 第七章 | 总经理及其他高级管理人员 | 32 | | 第八章 | 监事会 | 34 | | 第一节 | ...